141 related articles for article (PubMed ID: 17225314)
1. Anti-HIV agents. Atazanavir vs. Kaletra.
TreatmentUpdate; 2005; 17(1):3-4. PubMed ID: 17225314
[No Abstract] [Full Text] [Related]
2. Anti-HIV agents. Kaletra + atazanavir.
TreatmentUpdate; 2005; 17(5):5. PubMed ID: 17219657
[No Abstract] [Full Text] [Related]
3. Anti-HIV agents. The Castle study: lopinavir vs. atazanavir.
TreatmentUpdate; 2008 Mar; 20(2):7-8. PubMed ID: 18661646
[No Abstract] [Full Text] [Related]
4. Drug interactions. Kaletra and atazanavir.
TreatmentUpdate; 2006; 18(3):7-8. PubMed ID: 17211919
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
6. A king in the CASTLE? Optimum initial HIV protease inhibitor.
Torti C; Frank I
Lancet; 2008 Aug; 372(9639):604-6. PubMed ID: 18722849
[No Abstract] [Full Text] [Related]
7. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
[TBL] [Abstract][Full Text] [Related]
8. [New treatment options for HIV-infected patients].
Wehr A
Dtsch Med Wochenschr; 2004 May; 129(19):1093. PubMed ID: 15174468
[No Abstract] [Full Text] [Related]
9. Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.
Prescrire Int; 2009 Jun; 18(101):104. PubMed ID: 19637415
[TBL] [Abstract][Full Text] [Related]
10. [Atazanavir-induced nephrolithiasis].
Valencia ME; Moreno V
Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):134-5. PubMed ID: 19246127
[No Abstract] [Full Text] [Related]
11. [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
MMW Fortschr Med; 2003 Dec; 145(50):61. PubMed ID: 14963981
[No Abstract] [Full Text] [Related]
12. Reyataz dosing options discussed. Excerpts from the FDA atazanavir hearing.
Huff B
GMHC Treat Issues; 2003 Jun; 17(6):8-11. PubMed ID: 12913962
[No Abstract] [Full Text] [Related]
13. Anti-HIV agents. Once-daily lopinavir/ritonavir (Kaletra).
TreatmentUpdate; 2004 Mar; 16(2):3-4. PubMed ID: 17219667
[No Abstract] [Full Text] [Related]
14. [New data on atazanavir/r]].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():81-3. PubMed ID: 16385887
[No Abstract] [Full Text] [Related]
15. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Atazanavir in treatment-experienced patients.
Sax PE
AIDS Clin Care; 2003 Sep; 15(9):78. PubMed ID: 14666914
[TBL] [Abstract][Full Text] [Related]
16. Anti-HIV agents. Atazanavir as a booster for protease inhibitors.
TreatmentUpdate; 2003; 15(4):1-2. PubMed ID: 17216850
[No Abstract] [Full Text] [Related]
17. Disappearance of renal stones in an HIV-1-infected patient after reduction of atazanavir dose.
Lanzafame M; Bonora S; Lattuada E; Calcagno A; Di Perri G; Concia E
AIDS Res Hum Retroviruses; 2014 Sep; 30(9):835-6. PubMed ID: 24998758
[No Abstract] [Full Text] [Related]
18. Boosted Reyataz: 48-week results.
Huff B
GMHC Treat Issues; 2004; 18(1-2):15. PubMed ID: 15119279
[No Abstract] [Full Text] [Related]
19. CASTLE study showed similar efficacy.
AIDS Patient Care STDS; 2008 Mar; 22(3):253. PubMed ID: 18348342
[No Abstract] [Full Text] [Related]
20. Anti-HIV agents. A trial of Kaletra monotherapy.
TreatmentUpdate; 2008 Jan; 20(1):2-3. PubMed ID: 18320691
[No Abstract] [Full Text] [Related]
[Next] [New Search]
